Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval as a Adjuvant Therapy for Renal Cell Carcinoma
Shots: The approval is based on the P-III KEYNOTE-564 trial evaluating Keytruda (200mg, IV, q3w for 1yrs.) vs PBO in a ratio (1:1) in 994 […]